News and Resources

Dexpramipexole Kv 7 Company News

08.04.18

American Society of Hematology: “Dexpramipexole: a new antieosinophil drug?”

Discover this News

05.22.18

NIAID Now: Repurposed Drug Shows Promise for Treating Rare Eosinophilic Diseases

Discover this News

05.10.18

Knopp Biosciences Announces Publication of Phase 2 Trial Results of Dexpramipexole in Hypereosinophilic Syndromes (HES) in Blood

Discover this News

01.01.18

American Society of Hematology: “Dexpramipexole as an oral steriod-sparing agent in hypereosinophilic syndromes”

Discover this News

01.01.18

The Laryngoscope: “Dexpramipexole Depletes Blood and Tissue Eosinophils in Nasal Polyps”

Discover this News

09.06.17

Knopp Biosciences and APFED Announce Partnership to Advance Awareness of Hypereosinophilic Syndromes

Discover this News

01.16.17

Elsevier: “The targeted eosinophil-lowering effects of dexpramipexole in clinical studies”

Discover this News

1 2 3

Knopp Disclaimer

Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are undergoing clinical study to verify their safety and effectiveness.